Video
Dr. Yorio on T-DM1 in HER2-Mutant Lung Cancer Treatment
Author(s):
Jeff Yorio, MD, discusses a small phase II study that is looking at using ado-trastuzumab emtansine to treat patients with HER2-mutant metastatic lung cancer.
Jeff Yorio, MD, medical oncologist, Texas Oncology, discusses a small phase II study that is looking at using ado-trastuzumab emtansine (T-DM1; Kadcyla) to treat patients with HER2-mutant metastatic lung cancer.
Patients involved in the study were heavily pretreated with traditional treatments for metastatic lung cancer, including chemotherapy and immunotherapy. The partial response rate to ado-trastuzumab emtansine in this study was 44% and stable disease was observed in 39% of patients.
Ado-trastuzumab emtansine is not yet approved for use in lung cancer; however, the National Comprehensive Cancer Network is recommending the drug for HER2-mutant patients with metastatic lung cancer.
